Immunotherapy represents a recent breakthrough in cancer treatment fueled by the accelerating mechanistic understanding of how transformed cells subvert our immunosurveillance. Therefore, developing therapeutic strategies that enhance systemic immunosurveillance in a controllable manner has become one of the major interests in this field. Among different agents, small molecule activators (agonists) of the cGAS-STING pathway have recently attracted attention because they are expected to synergize with immunotherapies and enhance anti-cancer immune response by upregulating the interferon response. We previously identified a compound, BDW568, that was shown to activate the interferon pathway in a STING-dependent manner. Surprisingly, follow-up studies demonstrated that cGAS and STING are not direct target(s) of BDW568. Therefore, observed phenotype suggests that BDW568 acts either through (1) binding to an unknown regulator of the cGAS-STING pathway, or (2) by generating an unknown signaling molecule independent of 2?,3?-cGAMP, the endogenous STING agonist. In the proposed study we will identify the cellular target of BDW568 responsible for the previously discovered phenotype using two orthogonal strategies. In the first approach, we will synthesize BDW568-based photoaffinity probes and use them to label any protein that binds to BDW568. Labeled target(s) will be identified by a whole-cell lysate pulldown experiments coupled with mass spectrometry (MS). In the second approach, we will use CRISPR-Cas9 to individually knock out all the genes that are known to interact with STING or associate with interferon pathways. The knockout of the BDW568 target should demonstrate either resistance to the compound or elevation of the basal interferon level without BDW568 through STING. Any target candidate that emerges from either one of these approaches will be rigorously validated according to the standards of the field to establish that observed phenotype is due to on-target engagement. Successful completion of proposed studies will expand the target space within cGAS-STING pathway. These insights will lead to additional opportunities for developing adjuvant immunotherapies as well as expand our understanding of innate immune response in mammalian cells.
Zhu, Qingfu; Heon, Mikala; Zhao, Zheng et al. (2018) Microfluidic engineering of exosomes: editing cellular messages for precision therapeutics. Lab Chip 18:1690-1703 |
Pacelli, Settimio; Basu, Sayantani; Berkland, Cory et al. (2018) Design of a cytocompatible hydrogel coating to modulate properties of ceramic-based scaffolds for bone repair. Cell Mol Bioeng 11:211-217 |
Wessinger, Carolyn A; Kelly, John K; Jiang, Peng et al. (2018) SNP-skimming: A fast approach to map loci generating quantitative variation in natural populations. Mol Ecol Resour 18:1402-1414 |
Zhang, Peng; Crow, Jennifer; Lella, Divya et al. (2018) Ultrasensitive quantification of tumor mRNAs in extracellular vesicles with an integrated microfluidic digital analysis chip. Lab Chip 18:3790-3801 |
Klaus, Jennifer R; Deay, Jacqueline; Neuenswander, Benjamin et al. (2018) Malleilactone Is a Burkholderia pseudomallei Virulence Factor Regulated by Antibiotics and Quorum Sensing. J Bacteriol 200: |
Abisado, Rhea G; Benomar, Saida; Klaus, Jennifer R et al. (2018) Bacterial Quorum Sensing and Microbial Community Interactions. MBio 9: |
Hill, Tom; Unckless, Robert L (2018) The dynamic evolution of Drosophila innubila Nudivirus. Infect Genet Evol 57:151-157 |
Bandyopadhyay, Arnab; Wang, Huijing; Ray, J Christian J (2018) Lineage space and the propensity of bacterial cells to undergo growth transitions. PLoS Comput Biol 14:e1006380 |
Kaplan, Sam V; Limbocker, Ryan A; Levant, Beth et al. (2018) Regional differences in dopamine release in the R6/2 mouse caudate putamen. Electroanalysis 30:1066-1072 |
Reiner, David J; Lundquist, Erik A (2018) Small GTPases. WormBook 2018:1-65 |
Showing the most recent 10 out of 134 publications